ABBV vs JNJ
AbbVie and Johnson & Johnson, both Healthcare
Johnson & Johnson is the larger company at $635B against $505B. On trailing earnings JNJ is the cheaper of the two at a P/E of 40.0 against 80.7, a gap that is only a bargain if the two are growing at similar rates. Over the past year JNJ returned +40% against +28% for ABBV. The RyuScore puts JNJ ahead, 68 against 48 out of 100.
| Figure | ABBV | JNJ |
|---|---|---|
| Last close | $286 | $264 |
| Market cap | $505B | $635B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 80.7 | 40.0 |
| Dividend yield | 2.3% | 2.0% |
| 1-year return | +28% | +40% |
| 5-year return | +209% | +88% |
| RyuScoresector-relative, 1–10 | 48/100 | 68/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
AbbVie
Revenue of $17B in Q2 2026, net income $3.6B. Its largest reported line is SKYRIZI, 36% of the disclosed total.
Johnson & Johnson
Revenue of $25B in Q3 2026, net income $210M. Its largest reported line is DARZALEX, 19% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.